Trillium Renewable Chemicals | $13,000,000 | (May 7, 2026)
RadixArk | $100,000,000 | (May 7, 2026)
Astrada | $3,800,000 | (May 7, 2026)
Actym Therapeutics, Inc.
United States
- Berkeley, CA
- 20/10/2023
- Series A
- $59,500,000
Actym Therapeutics is a cutting-edge biotech focused on the discovery and development of novel immuno-oncology therapies.
- Industry Biotechnology Research
- Website https://actymthera.com/
- LinkedIn https://www.linkedin.com/company/actym-therapeutics-inc/about/
Related People
Christopher ThanosCo Founder
United States -
Belvedere Tiburon, California
• Significant entrepreneurial and leadership experience in the biotechnology industry
• 30 years R&D experience
• Design, engineering, and production of cell therapies, ADC's, enzymes, and alternative scaffolds
• Comprehensive understanding of pipeline flow, from lead optimization to IND, to clinical POC
• Established skills in competitive intelligence, strategy, due diligence, portfolio management
• Inventor on multiple issued patents covering biotherapeutics
• First author publications in high impact factor journals such as Science, PNAS, JACS
• Effectively managed large teams
• Invited speaker, workshop leader, conference chair at several international meetings
XCaliber Health | $6,500,000 | (May 7, 2026)
Cytospire Therapeutics Ltd | $82,984,705 | (May 7, 2026)
QuantWare | $178,775,560 | (May 7, 2026)
MOSH | $13,000,000 | (May 7, 2026)
InstaSwitch | $4,700,000 | (May 7, 2026)
Smartness | $55,270,590 | (May 7, 2026)
Scout Space | $18,000,000 | (May 7, 2026)
Altara | $7,000,000 | (May 7, 2026)
District | $14,700,000 | (May 7, 2026)